Modulation of allergic immune responses by using adequate adjuvants is a promising concept for future immunotherapy of type I hypersensitivity. In the present study, recombinant Bet v 1 (rBet v 1, the major birch pollen allergen) was conjugated to cross-linked crystalline surface layer proteins ( 
Introduction
In the last few years, evidence has accumulated that antagonizing activities of IL-4 and IFN-γ produced by different T cell subsets (T h 2 and T h 1) play a pivotal role in the allergic immune response in mice and humans (1) (2) (3) (4) . Allergic individuals demonstrate T h 2-like immune responses to allergenic molecules, leading to high antibody levels, including the production of IgE antibodies. Non-allergic practised since 1911 (6) , the underlying mechanism of its effectiveness is still unclear. Recent studies investigating patients which had undergone successful SIT indicated a modulation of the immune response at the level of T lymphocytes. Successful SIT was associated with a shift to a more T h 0/T h 1-like cytokine pattern (decreased IL-4-production and/or increased IFN-γ production) in allergenspecific T cells from treated patients (10) (11) (12) (13) (14) .
Thus, a redirection of regulatory T cells towards T h 0/T h 1-like responses could represent a promising strategy in therapy and maybe even in prophylaxis of type I allergy (15) . One possibility to influence the immune response to an antigen is the use of adjuvants and/or carriers inducing the desired type of immune response. It has long been known that bacterial components favor T h 1-like cellular immune responses. Bacterial antigens result in immune responses with T h 1 characteristics (4, (16) (17) (18) (19) . Recently an inverse association between tuberculin responses and atopic disorder became evident (20) . Crystalline bacterial surface layers (SL) are common archeobacterial and eubacterial cell surface components. They form two-dimensional crystalline arrays (21) and can be used as carrier and adjuvants. In a mouse system, crosslinked carbohydrate/SL conjugates induced typical T h 1-like immune responses (22, 23) .
The objective of the present study was to characterize allergen-specific T cell populations induced by allergen/SL conjugates. In our model system Bet v 1, the major birch pollen allergen (24, 25) , was used for several reasons. The immune response of allergic and non-allergic individuals to Bet v 1 has been extensively characterized in the recent past (5, 26) . In addition, it is available as standardized, recombinant protein in unlimited quantities. rBet v 1 has been shown to display identical qualities compared to natural Bet v 1 in vitro and in vivo (26) (27) (28) .
We analyzed the cytokine production and epitope recognition of Bet v 1-specific TCL and TCC induced either with rBet v 1 or with rBet v 1/SL and investigated the mechanism of the observed differences in T h subset distribution. Our investigation supports the idea of using bacterial carriers as adjuvants in vaccines for SIT of type I allergy in the future.
Methods

Patients
Peripheral blood was obtained from birch pollen-allergic patients. Type I allergy to birch pollen was proved by typical case history, positive skin tests and positive radioallergosorbent test. Furthermore, all patients investigated displayed IgE binding to rBet v 1 in immunoblot analyses (not shown).
Allergen and allergen/SL conjugates Purified rBet v 1 was obtained from Biomay (Linz, Austria). SL protein was prepared from two Gram-positive bacterial strains, Bacillus sphaericus CCM 2177 (29) and Thermoanaerobacter thermohydrosulfuricus L111-69 (30) . Cells were broken up by sonication to obtain cell walls. SL was then extracted using guanidine hydrochloride. Non-soluble peptidoglycan was removed by ultracentrifugation. During dialysis, the SL formed self assembly products. Glutaraldehyde fixation was performed as described (31) , only the concentration of glutaraldehyde was reduced to 0.05%. rBet v 1 was coupled to the fixed SL self assembly products after activation of carboxyl groups of the SL by 1-ethyl-3, 3Ј-(dimethyl-aminopropyl)-carbodiimide as previously described (32) . SL were controlled by SDS-PAGE and negative stain electron microscopy before and after fixation and conjugation. The rBet v 1/SL contained 30-50 µg rBet v 1/mg SL (w/w), which corresponds to~0.3 mol allergen/mol SL protomer. Their sizes ranged from~1 to 5 µm. Conjugation of the allergen to SL and the products have been previously described (33) . rBet v 1/SL containing cross-linked SL of either strain were combined at equivalent amounts. This homogeneous mixture of conjugates was used throughout the study.
Immunological characterization of rBet v 1/SL
The reactivity of rBet v 1 and rBet v 1/SL was comparable on a molar basis. This was tested in ELISA inhibition experiments using human Bet v 1-specific IgE as described before (26) . Moreover, epitope composition, proliferation inducing capacity and kinetics of cytokine production were studied using characterized Bet v 1-specific TCC (5, 33) .
Specificities of rBet v 1-and SL-specific TCL and TCC TCL and TCC were obtained according to a technique described previously (5) . Briefly, 1-1.5ϫ10 6 peripheral blood mononuclear cells (PBMC) were either stimulated with 20 µg rBet v 1 or with rBet v 1/SL containing also 20 µg Bet v 1 bound to 300 µg SL in 2 ml Ultra Culture medium (BioWhittaker, Walkersville, MD) supplemented with 2 mM glutamine and 20 µM 2-mercaptoethanol in 24-well flat-bottomed culture plates (Costar, Cambridge, MA). After 5 days of culture, human rIL-2 (10 U/ml; Boehringer Mannheim, Mannheim, Germany) was added and the culture continued for additional 7 days. Viable T cell blasts were then separated on FicollHypaque (Pharmacia, Uppsala, Sweden). These cells were investigated for secondary proliferative responses and the pattern of cytokine production. In addition, TCL blasts of five patients were cloned by limiting dilution (0.5 cells/well) in 96-well U-bottom plates (Nunclone; Nunc, Copenhagen, Denmark) in the presence of 2ϫ10 5 irradiated (60 Gy) allogeneic PBMC as feeder cells, 1% phytohemagglutinin (PHA; Gibco, Grand Island, NY) (v/v) and rIL-2 (4 U/well) in the medium described above. Growing microcultures were then expanded at weekly intervals with fresh feeder cells and rIL-2. The specificity of the clones was assessed in proliferation assays as described (5) . A stimulation index of Ͼ10 was considered positive.
A panel of 50 dodecapeptides according to the Bet v 1 sequence and overlapping for nine amino acids (Cambridge Research Biochemicals, Cambridge, UK) was used to define the T cell epitopes of rBet v 1-specific clones. Peptides were used at 5 µg/ml for the proliferation assays.
Analysis of phenotype and cytokine production
The phenotype of the TCC was analyzed by flow cytometry as described (5) For cytokine production of TCL and TCC induced with either rBet v 1 or rBet v 1/SL, 10 6 T cells were incubated with 5ϫ10 5 irradiated (60 Gy) autologous PBMC in 1 ml of culture medium in the presence of 10 µg rBet v 1. SL-specific TCC were stimulated with 150 µg SL. Cultures containing PBMC plus antigen and T cells plus PBMC without antigen served as negative controls. Supernatants were collected after 24 h. IL-4 and IFN-γ levels in the supernatants were measured using commercial ELISA systems (Medgenix Diagnostics, Fleurus, The Netherlands). Detection limits were 1.5 pg/ml for IFN-γ and 2 pg/ml for IL-4. For the classification of TCC, exclusive IFN-γ production or high IFN-γ/IL-4 ratio (10 or higher) was considered a T h 1-like and exclusive IL-4 production or low IFN-γ/IL-4 ratio (0.1 or less) a T h 2-like cytokine pattern. TCC which produced considerable amounts of IFN-γ and IL-4 were labeled T h 0-like TCC. In some TCC no cytokines could be detected in spite of high proliferative responses. These TCC were also attributed to the T h 0 subset.
To assay IL-12 production, 2ϫ10 6 PBMC/ml were cultured for 24 h with medium, rBet v 1 (10 µg/ml), rBet v 1/SL (10 respectively 150 µg/ml) or SL (150 µg/ml) alone. The concentration of IL-12 in the supernatants of these cultures was tested in ELISA assay systems specific for total IL-12p40 (p40/p40 and p40/p35 dimers; Medgenix) or the IL-12p70 heterodimer (Quantikine HS; R&D Systems, Minneapolis, MN). Staphylococcus aureus Cowan strain I (SAC), a strong IL-12 inducing agent (34) , was used as positive control (Pansorbin 1:10000; Calbiochem, La Jolla, CA).
Stimulation of established Bet v 1-specific TCC with Bet v 1/SL TCC cells (10 6 ) established with rBet v 1 (5) were stimulated with autologous PBMC and rBet v 1 (5 µg/ml) or rBet v 1/ SL respectively. Thereafter supernatants were collected as described above and analyzed for IFN-γ and IL-4.
IL-12 inhibition experiments 20c2, a strongly neutralizing mAb (35) , kindly provided by R. Chizzonite (Hoffmann-LaRoche, Nutley, NJ), was used at a concentration of 50 µg/ml. In pilot experiments, this concentration was shown to inhibit 74 Ϯ 6% of the effect of 500 pg huIL-12p70 (R&D Systems) in a PHA-blast proliferation assay (36) . Clone cells (10 6 ) were incubated with either rBet v 1/SL or rBet v 1/SL plus anti IL-12 or an isotype-matched control antibody (rat IgG1 50 µg/ml; PharMingen). The antibodies were added to the cultures 30 min prior to the antigens. Non-irradiated PBMC were used as antigen-presenting cells (APC). Supernatants were recovered and subjected to ELISA as mentioned above. The cytokine levels produced within the control cultures (PBMC plus respective antigen) were subtracted from the results obtained with the TCC.
Statistics
Cytokine production was analyzed by Wilcoxon's signed rank test and univariate analysis of variance subsequent to square root transformation.
Results
TCL induced by rBet v 1 and rBet v 1/SL TCL were established from peripheral blood of birch pollenallergic donors using either rBet v 1 or rBet v 1/SL as initial 6 ) were stimulated with 20 µg/2 ml rBet v 1 alone or rBet v 1/SL for 5 days and 20 U huIL-2 were added. At day 12 the TCL were re-stimulated with rBet v 1 and autologous irradiated APC. Supernatants were collected after 24 h and the concentrations of IFN-γ and IL-4 were determined by ELISA.
a P ϭ 0.003 (Wilcoxon's signed rank test).
stimulant. As shown in Table 1 Table 2 .
Epitope mapping
Testing allergen-specific TCC with 50 overlapping epitopes spanning the whole Bet v 1 sequence revealed 13 different T cell epitopes ( Table 2 ). The epitopes were scattered over the whole molecule. No difference was observed in the distribution of epitopes recognized by the TCC derived from either rBet v 1 or rBet v 1/SL-induced TCL. No epitope was associated with a particular T h subset.
Phenotype and cytokine production FACS analyses revealed that all TCC expressed TCR αβ. Two CD4 -CD3 ϩ CD8 ϩ clones were detected. One was derived from a rBet v 1-stimulated TCL and the other one was SL specific (induced by rBet v 1/SL). The remaining 51 TCC belonged to the T h phenotype (CD3 ϩ CD4 ϩ CD8 -).
After stimulation of TCC with rBet v 1, supernatants were analyzed for their content of IFN-γ and IL-4 (Table 3) . SLspecific TCC were stimulated with SL protein alone (data not shown). The CD4 ϩ clones were then divided into T h subsets according to the IFN-γ/IL-4 ratio. The results are summarized in Fig. 1 . As expected, the majority of TCC (12 of 22, 55%) derived from allergen-stimulated TCL displayed a T h 2-like pattern of cytokine production. Within TCC isolated from rBet v 1/SL activated TCL, a lower percentage of T h 2-like TCC (4 of 19, 21%) was observed. Concomitantly, the number of TCC producing T h 0 and T h 1-like patterns of cytokines increased (15 of 19, 79%) . This increase in T h 0/T h 1 subsets appeared to be due to the increased IFN-γ production as indicated by the mean values of IFN-γ (399 Ϯ 935 versus 893 Ϯ 1223 pg/ml), rather 0  37  3020  2480  0  47  2840  934  0  49  30  0  1   3  7 2  0  1 7 2  2  75  0  0  0  83  0  2  2  86  0  2182  2  88  0  2332  2  16  280  1762  0  27  0  210  2   4  25  180  2000  2  7  2730  338  0  36  0  0  0  37  0  0  0   5  1 2  8 5  0  1  16  0  31  2  18  0  0  0  20  0  796  2  31  65  2402  2  33  150  2515  2  34  160  400  0  110  520 than to changes in IL-4 (801 Ϯ 961 versus 932 Ϯ 971 pg/ ml). Using square root transformation and variance analysis, the differences in IFN-γ production observed with both stimuli were statistically significant (P ϭ 0.009). SL-specific CD4 ϩ TCC produced high concentrations of IFN-γ and no or only low concentrations of IL-4 (1202 Ϯ 1475 and 75 Ϯ 220 pg/ ml). Thus, eight of 10 (80%) TCC belonged to the T h 1-like T h subset and two of 10 TCC to the T h 0-like subset (Fig. 1) .
Induction of IL-12
IL-12 is a pivotal inducer of T h 1 responses (37). rBet v 1/SL and SL alone induced the synthesis of high levels of IL-12 in PBMC. Both IL-12p40 (total dimers) and also the bioactive IL-12p70 heterodimer could be demonstrated (Table 4) . a In units of pg/ml measured by IL-12 p40/p70-specific ELISA. Supernatants of 2ϫ10 6 PBMC were collected after 24 h stimulation with rBet v 1 (10 µg/ml), SL (150 µg/ml), rBet v 1/SL conjugate or SAC (1:10,000). Induction of IFN-γ in established Bet v 1-specific TCC by rBet v 1/SL IL-12 not only primes for stable IFN-γ production during T cell differentiation, but has also been shown to induce transient IFN-γ production in already established T h 2 TCC (37). To study the effect of rBet v 1/SL in this respect, additional rBet v 1-derived TCC were investigated. As shown in Fig. 2 , stimulation with rBet v 1/SL induced an elevated IFN-γ/IL-4 ratio in culture supernatants when compared with rBet v 1-stimulated TCC. These changes were due to a significant increase of IFN-γ (P ϭ 0.003, Wilcoxon's signed rank test), while the reduction of concentration of IL-4 was not significant.
IL-12 inhibition experiments
To evaluate the role of IL-12 in mediating the effects of rBet v 1/SL on T cell cytokine production, neutralizing mAb to huIL-12 were added to cultures of rBet v 1-specific TCC stimulated by rBet v 1/SL. The increase of the IFN-γ/IL-4 ratio promoted by the SL conjugates could be reversed by anti-IL-12 mAb, but not by isotype-matched control antibodies (Fig. 2) .
Discussion
SIT is an efficient form of treatment of type I allergy (6) (7) (8) (9) . The mechanism of its effectiveness is still unclear, although increasing evidence evolves indicating a working mechanism on the level of regulating T cells (10) (11) (12) (13) (14) . The molecular characterization of allergens, the availability of the major allergens as recombinant proteins together with the knowledge of epitopes open possibilities to develop new allergy vaccines (15, 38, 39) . One possibility to modulate the typical allergic T h 2-like immune response and to direct it towards T h 0 or T h 1 might be the administration of allergens together with appropriate adjuvants. Bacterial products have been shown to induce T h 1-like immune responses (4, (17) (18) (19) (20) . In this respect, cross-linked SL of Gram-positive eubacteria have been shown to be effective (23) . Therefore, in the present study bacterial SL were investigated for their usefulness as carrier/adjuvants for allergens.
TCL and TCC derived from the peripheral blood of birch pollen-allergic individuals were established using rBet v 1/ SL. T lymphocyte cultures were characterized and compared to cultures which had been produced in parallel using rBet v 1 alone. Oligoclonal Bet v 1-specific TCL induced with rBet v 1/SL revealed a significantly increased IFN-γ production when re-stimulated with rBet v 1 alone, as compared to TCL initiated with rBet v 1 and re-stimulated with rBet v 1 ( Table  1) . The presence of IFN-γ in the TCL-induction phase has been described to lead to a preferential development of TCC with a T h 1-like phenotype (40) . To investigate this mechanism we cloned TCL that had been induced with rBet v 1 or rBet v 1/SL respectively. Indeed, the majority of TCC derived from the TCL which had been initiated with rBet v 1 (55%) displayed a typical T h 2-like cytokine production pattern. Due to a significant increase of IFN-γ levels, less T h 2-like (21%) and increased numbers of IFN-γ-producing TCC were obtained from TCL initially stimulated with rBet v 1/SL. Most of the TCC specific for SL protein (80%) expressed a T h 1-like cytokine production pattern (Fig. 1) . The induction of particular cytokines in responding T lymphocytes depends on the expression of certain costimulatory surface molecules on APC and the presence of certain mediators in the microenvironment. Due to their size of 1-5 µm, a targeting of the rBet v 1/SL to macrophages, which are the most efficient phagocytic APC (41), may be assumed. Macrophages apparently are specialized APC in the promotion of T h 1 immune responses. This can be explained by the production of large amounts of IL-12, a heteromeric cytokine produced by activated macrophages. IL-12 elicits IFN-γ production and thereby T h 1 responses, and is induced by intracellular parasites and bacterial products (34) . The presence of IL-12 in the initial cultures may be responsible for the observed effects in our study. Indeed, we could show that in PBMC high levels of IL-12 (including the bioactive IL-12p70 heterodimer) were induced by SL or rBet v 1/SL, while allergen alone had no effect on the basal level of this cytokine. IL-12 has been described to elicit IFN-γ production in TCC of the T h 2 type (37) . To test whether IL-12 is an important factor contributing to the effects observed with our bacterial SL conjugates, we stimulated rBet v 1-induced allergen-specific TCC with rBet v 1/SL and compared IFN-γ/IL-4 ratios in response to rBet v 1 or rBet v 1/SL. As expected, stimulation with rBet v 1 associated with bacterial SL led to increased levels of IFN-γ production by TCC. This phenomenon could be reversed by the addition of neutralizing anti-IL-12 mAb, underlining the importance of IL-12 for the deviation induced by SL conjugates (Fig. 2) . In addition other factors may be involved, e.g. we cannot rule out that the observed modulation of the T cell response are partly due to the particularization per se (42) , also an increased antigen dose and peptide load per APC might contribute to the skewing of Th subsets (43, 44) .
The T cell epitopes of rBet v 1-and rBet v 1/SL-induced TCC were scattered over the whole Bet v 1 molecule (5) . No association between particular T h subsets and certain epitopes on the allergen could be observed. Therefore, no evidence for the selection of T h 1-associated specificities within the allergen molecule (which would have been of special therapeutical interest) could be observed. In our experiments SL had no influence on the induction of CD8 ϩ TCC. Only two CD8 ϩ TCC were isolated. One of each was derived from rBet v 1 respectively rBet v 1/SL-induced TCL, and both produced IFN-γ and IL-4 (45).
In conclusion, the results of our study indicate that bacterial components such as SL may be suitable carriers for allergens used as immunotherapeutic vaccines for SIT of type I allergy in the future. 
